Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate dose cyclophosphamide and G-CSF-Reference-Cited by-同舟云学术

Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate dose cyclophosphamide and G-CSF

Published:1997-01 Issue:1 Volume:21 Page:21-27
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Morton J.,Morton A.,Bird R.,Hutchins C.,Durrant S.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference18 articles.

1. Autologous bone marrow transplantation in haematological malignancies;Gordon;Am. J. Clin. Oncol.,1991

2. Bone marrow transplantation for solid tumours — prospects;Frei;J. Clin. Oncol.,1989

3. The evolving role of peripheral stem cell transplantation following high-dose therapy for malignancies;Kessinger;Blood,1991

4. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants;To;Bone Marrow Transplant.,1992

5. Single high dose of cyclophosphamide enables collection of high numbers of hemopoietic stem cells from peripheral blood;To;Exp. Haematol.,1990

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection;Transfusion and Apheresis Science;2021-06

2. Variant rs1801157 in the 3’UTR of SDF-1ß Does Not Explain Variability of Healthy-Donor G-CSF Responsiveness;PLOS ONE;2015-03-24

3. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation;Journal of Clinical Apheresis;2014-06-19

4. Oral Chemotherapeutic Agents;Encyclopedia of Drug Metabolism and Interactions;2012-05-15

5. Mobilisation strategies for normal and malignant cells;Pathology;2011-10